Shackelford Pharma is built on Dr. Shackelford's real world experience and insights. This represents over 25,000 real patient interactions with real outcomes. Shackelford's team has analyzed patient outcomes to identify the most promising therapeutic candidates for development. Shackelford Pharma has exclusive access to these insights.
Our therapeutic focus
Shackelford is focused on epilepsy. Our drug candidate (SP1707) is supported by 133 patient treatment years of data from patients under the care of Dr. Shackelford. Our mission is to bring this new medicine through the development and FDA regulatory process to benefit people with epilepsy with unmet medical needs.
43 FDA Drug Approvals
Our world-class R&D team has over 220 years of collective pharmaceutical drug development experience. All have enjoyed key leadership roles in the development of 43 drugs that have been approved by the FDA. This includes 7 which have sold over $1B per year and 6 epilepsy drugs.
"After CNN featured Alan's groundbreaking treatment of a child with Dravet Syndrome, parents brought in kids from all over the USA and world. The parents would give up everything for the treatment and products their kids needed!"
